Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 927Neoplasms 612Breast Neoplasms 611Colorectal Neoplasms 458Neoplasm Metastasis 398Ovarian Neoplasms 333Prostatic Neoplasms 316Melanoma 316Lung Neoplasms 294Multiple Myeloma 293Recurrence 281Squamous Cell Carcinoma of Head and Neck 248Stomach Neoplasms 232Pancreatic Neoplasms 231Leukemia, Myeloid, Acute 224Triple Negative Breast Neoplasms 193Endometrial Neoplasms 190Carcinoma, Renal Cell 183Lymphoma, Non-Hodgkin 178Carcinoma, Hepatocellular 178Small Cell Lung Carcinoma 166Leukemia, Lymphocytic, Chronic, B-Cell 158Advanced Solid Tumors 158Lymphoma, Follicular 150Lymphoma, Large B-Cell, Diffuse 141Urinary Bladder Neoplasms 140Lymphoma 138Advanced Solid Tumor 137Uterine Cervical Neoplasms 136Head and Neck Neoplasms 134

Interventions

lutikizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Hidradenitis Suppurativa × 1 year × Clear all
NCT07428941 2026-02-24

LegitHealth PH

AI Labs Group S.L

Completed
9 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Nevus, Pigmented, Skin Diseases, Urticaria, Hidradenitis Suppurativa, Keratosis, Actinic

NCT05243966 2026-02-19

MASTRR

Aroa Biosurgery Limited

Recruiting
800 enrolled
Gastrointestinal

Pressure Ulcer, Pilonidal Sinus, Rectal Fistula, Hidradenitis Suppurativa

NCT05139602 2026-02-13

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

AbbVie

Phase 2 Active not recruiting
210 enrolled

Hidradenitis Suppurativa

Data powered by HemOnc (CC BY 4.0) Colophon âš¡